Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-164

8 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 01)

Image001 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 01)
Chemical structure diagram depicting the active ingredient Losartan Potassium, showing its molecular framework including rings, bonds, and potassium ion representation.*
FDA Label Image

Image002 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 02)

Image002 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 02)
A line graph depicting the percentage of patients with a primary endpoint over study months, comparing Atenolol (dotted line) and Losartan potassium (solid line). The x-axis represents study months up to 66, and the y-axis shows percent of patients up to 16%. Annotations indicate an adjusted risk reduction of 13% with Losartan potassium, p=0.021.*
FDA Label Image

Image003 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 03)

Image003 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 03)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan potassium. The x-axis shows study months (0 to 66) and the y-axis shows the percentage of patients affected (0% to 8%). Losartan potassium shows a lower percentage of patients with strokes than Atenolol, indicating an adjusted risk reduction of 25%, p=0.001.*
FDA Label Image

Image004 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 04)

Image004 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 04)
A forest plot comparing event rates and hazard ratios between Losartan Potassium and Atenolol across various patient subgroups for primary composite and stroke (fatal/non-fatal) outcomes. The chart displays data by age, gender, race, presence of ISH, diabetes, and history of cardiovascular disease, illustrating hazard ratios with 95% confidence intervals favoring either Losartan Potassium or Atenolol.*
FDA Label Image

Image005 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 05)

Image005 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 05)
A line graph comparing the percentage of patients with events over 48 months between Losartan potassium and placebo groups. The graph shows a risk reduction of 16.1% with Losartan potassium versus placebo, with a statistically significant p-value of 0.022. The x-axis represents time in months, and the y-axis represents the percentage of patients experiencing the event.*
FDA Label Image

72789163 Label (72789163)

72789163 Label (72789163)
Losartan Potassium 25 mg Tablets, USP film-coated tablets in a 90-count package. The label includes the NDC 72789-163-90, marked Rx only, and states it is marketed by PD-Rx Pharmaceuticals, Inc., and manufactured by Vivimed Life Sciences Private Limited in Tamilnadu, India. Storage instructions and a barcode are also included.*
FDA Label Image

72789164 Label (72789164)

72789164 Label (72789164)
Label for Losartan Potassium 50 mg tablets, USP, containing 90 film-coated tablets for oral use. Marketed and packaged by PD-Rx Pharmaceuticals, Inc. in Oklahoma City, OK, and manufactured by Vivimed Life Sciences Private Limited in Tamilnadu, India. The label includes storage instructions, barcode, NDC 72789-164-90, and a note for pharmacists to dispense with a medication guide.*
FDA Label Image

72789165 Label (72789165)

72789165 Label (72789165)
Label for Losartan Potassium Tablets USP 100 mg, containing 90 tablets. The label shows the product name, strength, and quantity along with storage instructions, bar code, and distributor information. Marketed by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK, and manufactured by Vivimed Life Sciences Private Limited, Tamilnadu, India. The label includes an NDC number and a notice for pharmacists to dispense with a medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.